A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

Trial Details

NCT ID
NCT05093907
Phase
PHASE1 / PHASE2
Sponsor
BeyondBio Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • BEY1107
  • Capecitabine
Locations (sample)
  • Seoul, Jongro-go, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Adult males and females aged over 19 years or older at the time of Informed Consent.
  • Histopathologically or cytologically diagnosed with colorectal cancer.
  • Patients with unresectable metastatic lesion(s).
  • Patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy (including fluoropyrimidine, o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →